Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Rhabdomyosarcoma
56%
Pediatric Oncology
50%
Pediatric Soft Tissue Sarcoma
37%
Clinical Trials
25%
Partial Response
25%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
25%
Patient Journey
25%
Volume Response
25%
Primary Tumor Size
25%
Standardized Uptake Value
25%
Response Evaluation Criteria in Solid Tumors (RECIST)
25%
Metastatic Rhabdomyosarcoma
25%
Progressive Disease
25%
European Guidelines
25%
Radiologic
25%
Tumor Volume
25%
Pediatric Radiology
25%
Accuracy Improvement
25%
Oncologic Imaging
25%
Artificial Intelligence Applications
25%
Pediatric
20%
Failure-free Survival
18%
Working Diagnosis
18%
Overall Survival
18%
Radiologists
16%
Artificial Intelligence
16%
Motion Artifact
16%
Blood Pool
14%
Liver
14%
Pediatric Rhabdomyosarcoma
12%
Stable Disease
12%
3-cycle
12%
Chemotherapy Cycles
12%
Complete Response
12%
Online Edition
12%
Senior Authors
12%
Process Language
8%
Risk of Error
8%
Clinical Documentation
8%
Innovative Solutions
8%
Driving Method
8%
New Dataset
8%
Natural Language Processing
8%
Privacy-preserving Training
8%
Synthetic Data Generation
8%
Improving Model
8%
Large Language Models
8%
Generic Model
8%
Workflow Optimization
8%
Model Privacy
8%
Medicine and Dentistry
Rhabdomyosarcoma
100%
Pediatrics
62%
Soft Tissue Sarcoma
56%
Clinical Trial
50%
Primary Tumor
25%
Cancer Staging
25%
Tumor
25%
Paediatric Radiology
25%
Cancer
25%
Progressive Disease
12%
Chemotherapy
9%
Proportional Hazards Model
9%
Diseases
9%
Failure Free Survival
9%
Overall Survival
9%
Fluorodeoxyglucose F 18
6%
Positron Emission Tomography-Computed Tomography
6%
Diffusion MRI
6%
Risk Stratification
6%
Radiation Therapy
6%
Maintenance Chemotherapy
6%
Quality of Life
6%
Metastatic Carcinoma
6%
Prognostic Factor
6%
Clinical Documentation
6%
Nursing and Health Professions
Tumor Volume
25%
Rhabdomyosarcoma
25%
Body Weight
25%
Polyethylene Terephthalate
25%
Childhood Cancer
25%
Fluorodeoxyglucose F 18
25%
Standardized Uptake Value
25%
Diseases
21%
Pediatrics
16%
Proportional Hazards Model
9%
Chemotherapy
9%
Overall Survival
9%
Failure Free Survival
9%
Lean Body Weight
7%
X-Ray Computed Tomography
7%
Surface Area
7%
Positron Emission Tomography-Computed Tomography
7%
Pediatrics Patient
7%
Soft Tissue Sarcoma
6%